Ingredient or product comparison
GHK-Cu Safe Long Term Use: Comparison Across Peptide Classes
GHK-Cu 8–24 months Injection site reaction (12%), mild erythema (8%) Copper chelation, gene expression modulation Research-grade compound (not FDA-approved as drug) Favorable. No cumulative toxicity signals in trials up to 2 years; safety beyond 24 months extr
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu
- 8–24 months
- Injection site reaction (12%), mild erythema (8%)
- Copper chelation, gene expression modulation
- Research-grade compound (not FDA-approved as drug)
- Favorable. No cumulative toxicity signals in trials up to 2 years; safety beyond 24 months extrapolated from animal data
- BPC-157
- 4–12 weeks
- Minimal reported; transient nausea (<5%)
- VEGF upregulation, angiogenesis
- Research-grade compound
- Limited long-term data. Most trials <3 months; chronic use safety profile not established
- TB-500 (Thymosin β4)
- 4–16 weeks
- Headache (6%), fatigue (4%)
- Actin sequestration, cell migration
- Short trial durations. Insufficient evidence for safety beyond 16 weeks
- Epitalon
- 10 days to 6 months
- None reported in published studies
- Telomerase activation, pineal regulation
- Very limited human trial data; most evidence from animal models
- Semaglutide (GLP-1)
- 68+ weeks
- GI distress (30–45%), gallbladder events (1.5%)
- GLP-1 receptor agonist
- FDA-approved
- Established long-term safety profile; continuous use demonstrated safe in trials exceeding 2 years